Shire Files To Offer Alternative Treatment for Gaucher Disease

Shire Human Genetic TherapiesMBBP client Shire plc (LSE: SHP, NASDAQ: SHPGY), a global specialty biopharmaceutical company, has announced that it has filed a treatment protocol for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Gaucher Disease. According to a Mass High Tech article, the move was at the request of the FDA, in view of a potential restriction on the availability of the current approved and marketed treatment the disease — Cerezyme by Genzyme. See the full Shire news release here.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s